Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.

MLA

Benjamini, Ohad, et al. “Safety and Efficacy of the BNT162b MRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.” Haematologica, vol. 107, no. 3, Mar. 2022, pp. 625–34. EBSCOhost, https://doi.org/10.3324/haematol.2021.279196.

APA

Benjamini, O., Rokach, L., Itchaki, G., Braester, A., Shvidel, L., Goldschmidt, N., Shapira, S., Dally, N., Avigdor, A., Rahav, G., Lustig, Y., Ben David, S. S., Fineman, R., Paz, A., Bairey, O., Polliack, A., Levy, I., & Tadmor, T. (2022). Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica, 107(3), 625–634. https://doi.org/10.3324/haematol.2021.279196

Chicago

Benjamini, Ohad, Lior Rokach, Gilad Itchaki, Andrei Braester, Lev Shvidel, Neta Goldschmidt, Shirley Shapira, et al. 2022. “Safety and Efficacy of the BNT162b MRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.” Haematologica 107 (3): 625–34. doi:10.3324/haematol.2021.279196.